Exploring the relationships between physiochemical properties of nanoparticles and cell damage to combat cancer growth using simple periodic table-based descriptors

• Joyita Roy and
• Kunal Roy

Beilstein J. Nanotechnol. 2024, 15, 297–309, doi:10.3762/bjnano.15.27

• ). However, metal oxides can change the TME conditions by supplying oxygen and suppressing hypoxia-inducible factor 1 and CD39/CD73 in T cells, which reduces the immunosuppression effect of tumors. Comparison with previously published literature This study successfully develops a QSPR model with a cell

Poly(1-vinylimidazole) polyplexes as novel therapeutic gene carriers for lung cancer therapy

• Gayathri Kandasamy,
• Elena N. Danilovtseva,
• Vadim V. Annenkov and
• Uma Maheswari Krishnan

Beilstein J. Nanotechnol. 2020, 11, 354–369, doi:10.3762/bjnano.11.26

• that the polyplex leads to a better internalization of the siRNA. This is also reflected in the differential modulation of gene targets associated with VEGF in the microarray analysis. The superior silencing of VEGF by the polyplex is also reflected in the reduced levels of hypoxia-inducible factor-1

Near-infrared dye loaded polymeric nanoparticles for cancer imaging and therapy and cellular response after laser-induced heating

• Tingjun Lei,
• Alicia Fernandez-Fernandez,
• Romila Manchanda,
• Yen-Chih Huang and
• Anthony J. McGoron

Beilstein J. Nanotechnol. 2014, 5, 313–322, doi:10.3762/bjnano.5.35

• hyperthermia (HT). HT is currently used in clinical trials for cancer therapy in combination with radiotherapy and chemotherapy. One of the potential problems of HT is that it can up-regulate hypoxia-inducible factor-1 (HIF-1) expression and enhance vascular endothelial growth factor (VEGF) secretion. Results

• of both transcription factors. Keywords: hypoxia-inducible factor-1; IR820; nanoparticle; poly(glycerol malate co-dodecanedioate) (PGMD); vascular endothelial growth factor; Introduction The synthesis and development of novel polymers and their use for nanoparticle (NP) synthesis has been an

• chemotherapy and radiotherapy. HT achieves therapeutic benefits by damaging cancer cell proteins and structures as a result of an increase in cell temperature. However, one of the potential problems is that hypoxia-inducible factor-1 (HIF-1) could be up-regulated by HT [10][11]. An overexpression of HIF-1 has